| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.1 |
| Gross profit | 0.1 | 0.1 |
| Net income | -6.1 | -7.2 |
| EPS (diluted, $ a share) | $-1.91 | $-3.93 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -16.1% |
|---|---|
| Gross margin | 61.7% |
10-Q filed with the SEC, NASDAQ: LGVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Longeveron Inc.: key numbers
- Share price
- $2.11Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Longeveron Inc.
All →Longeveron Financial Results
Longeveron Inc. reported Q3 2026 financial results and announced it has initiated a formal process to review strategic alternatives, including a potential sale, merger, or business combination. The company has retained Lucid Capital Markets as its financial advisor and is seeking a meeting with the FDA to discuss next steps for its HLHS program following Phase 2b trial results.
“With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program. At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our stockholders.”
Stephen H. Willard, Chief Executive Officer
Longeveron Leadership Change
Ms. Ursula Ungaro resigned from Longeveron Inc.'s Board of Directors and all associated committees effective November 1, 2026. Her departure was due to personal health issues and was not the result of any disagreement with the company's operations, policies, or practices.
Longeveron Clinical Trial Data
Longeveron announced updated Phase 2b ELPIS II trial results for laromestrocel in infants with hypoplastic left heart syndrome (HLHS). While the trial missed its primary efficacy endpoint of RVEF change, additional analysis showed the secondary endpoint of major adverse cardiac events (MACE) achieved statistical significance with only 1 event in the treatment arm versus 8 in the standard of care arm (P=0.043).
- Counterparty
- National Institutes of Health (NIH)
Longeveron Leadership Change
Dr. Nataliya Agafonova informed Longeveron Inc. of her decision to step down as Chief Medical Officer, effective October 14, 2026. The departure was disclosed under Item 5.02 of the company's 8-K filing.
Longeveron Clinical Trial Data
Longeveron announced that its Phase 2b ELPIS II trial evaluating laromestrocel for hypoplastic left heart syndrome (HLHS) failed to meet its primary efficacy endpoint of change in right ventricular ejection fraction at 12 months. Despite the failure, the company noted a favorable safety profile and plans to discuss exploratory clinical outcomes with the FDA to determine potential next steps. Consequently, the company has initiated cost containment measures and is exploring options to maximize shareholder value.
Longeveron Nasdaq/NYSE Compliance Notice
Longeveron Inc. has regained compliance with Nasdaq's $1.00 minimum bid price requirement after its Class A common stock maintained a closing price of at least $1.00 for 10 consecutive business days. The company had previously been under a deficiency notice since September 2025 and was granted two 180-day extension periods to resolve the issue. Nasdaq has officially closed the matter, securing the company's continued listing on The Nasdaq Capital Market.
- Counterparty
- Nasdaq